Bayer/GSK Levitra Has 16% Share Of New Scripts; 2003 Sales Reach $180 Mil.
Executive Summary
Bayer/GlaxoSmithKline's Levitra has a 16% share of new prescriptions in the erectile dysfunction disorder market, Bayer CFO Klaus Kuhn reported during a year-end investor meeting March 18
You may also be interested in...
Cialis, Levitra market share numbers
Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...
Cialis, Levitra market share numbers
Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...
Bayer Focuses Internally: In-Licensing, In-House R&D Are Priorities
Bayer will focus on seeking licensing deals for its pharmaceutical business after abandoning a search for a more extensive partnership, CEO Werner Wenning told analysts Nov. 11